Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Waters Corporation    WAT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

WATERS CRP : Waters Introduces Highest Performing UPLC Ever Engineered – the new ACQUITY UPLC I-Class

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/02/2011 | 12:30pm CEST
Waters Introduces Highest Performing UPLC Ever Engineered – the new ACQUITY UPLC I-Class
The New ACQUITY UPLC I-Class System Takes Separations Technology to the Next Level by Maximizing Peak Capacity and Extending the Performance of any MS Detector
Milford, Mass. - 2011-06-01

Waters Corporation (WAT:NYSE) today introduced the new Waters® ACQUITY UPLC® I-Class System, the highest performing UPLC® system ever engineered taking UltraPerformance LC® separations technology to the next level.  For scientists challenged by the most difficult separations, the ACQUITY UPLC I-Class features the lowest system dispersion and lowest carryover in the industry today. Low dispersion maximizes peak capacity thereby advancing chromatographic separations and optimizing the performance of any mass spectrometer.

“The scientific discoveries with the biggest potential to improve our lives often rely on samples and compounds that are the most difficult to understand. The ACQUITY UPLC I-Class System was designed specifically for the rapid pace of laboratories on the cutting edge of research,” said Art Caputo, President of the Waters Division. “Design and function of the I-Class are based on continuous customer input resulting in improvements in sub-two-micron separation that only the originator of the technology can exploit. Whether customers need to rapidly analyze sample-limited compounds amid a complex matrix or they seek to optimize the performance of any mass spectrometer on the market, ACQUITY UPLC I-Class enables scientists to solve their most complex separations and detection challenges.”

Keeping pace with today’s most advanced laboratories, the ACQUITY UPLC I-Class System excels when analyzing complex, sample-limited compounds.   Sample-limited compounds include high potency medications, trace levels of food or water contamination, and (advanced) sophisticated biotherapeutics.  These samples can represent complex separation challenges requiring an LC system that can maximize the benefits of sub-two-micron for faster throughput and optimized MS performance.

While there are many innovations built into the new ACQUITY UPLC I-Class, minimal system volume is a new key feature. Reduced system volume significantly decreases dispersion rates for reproducibly higher resolution and superior peak capacity. Reduced dispersion and small peak volumes extend the sensitivity of any mass spectrometer. Additionally, low dispersion footprint allows users to reduce their separation cycle times without impact to the separation as resolution is maintained even for ballistic gradients lasting less than one minute. Also importantly, new   design and materials dramatically reduce sample carryover effects, thus increasing user confidence in results.

The ACQUITY UPLC I-Class also features class leading flexibility and precise sampling capabilities. Depending on application needs, users can choose either the highest precision and lowest dispersion fixed-loop Sample Manager, or the world’s first low dispersion variable volume Sample Manager with a flow-through needle design, which delivers high-precision injections, excellent sample recovery, and lowest sample carryover optimizing the performance for even the most sensitive mass detectors.

ACQUITY UPLC family

Seven years ago, Waters pioneered a new category of chromatographic performance with the commercialization of sub-2-

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on WATERS CORPORATION
06/22 WATERS : Studies from Waters Corporation Reveal New Findings on Chromatography (..
06/22 WATERS : and Andrew Alliance sign co-marketing agreement
06/22 WATERS CORP /DE/ : Change in Directors or Principal Officers (form 8-K)
06/22 WATERS CORPORATION : Elects Flemming Ornskov to Board of Directors
06/21 WATERS : Presolicitation Notice - Waters Columns and Plates
06/15 WATERS : Andrews Alliance and Waters Sign Co-Marketing Agreement
06/14 WATERS : Presolicitation Notice - Waters corporation Mass Spec TQ-S Micro
06/13 WATERS : Stock Performance Review on Medical Supplies Industry -- Antares Pharma..
06/09 WATERS : Jeffrey Zonderman Joins RedShift BioAnalytics as its Chief Commercial O..
06/09 WATERS : and Wyatt Collaborate to Advance Polymer Analysis and Biopharmaceutical..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
06/22DJROYAL PHILIPS : Philips to Buy Electrical Geodesics for GBP29 Million
06/19 PERKINELMER : to buy Germany's Euroimmun for about $1.3 billion
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/17 PHILIPS CEO : uptake of connected care products progressing slowly
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
06/07 Danaher downgraded to Neutral from Buy at Janney
05/14 Tracking Ruane, Cunniff & Goldfarb's Portfolio - Q1 2017 Update
05/04 Best-Performing Stocks On Earnings This Season
04/25 Waters beats by $0.13, beats on revenue
04/24 Notable earnings before Tuesday?s open
Advertisement
Financials ($)
Sales 2017 2 258 M
EBIT 2017 687 M
Net income 2017 567 M
Finance 2017 345 M
Yield 2017 -
P/E ratio 2017 26,27
P/E ratio 2018 24,07
EV / Sales 2017 6,42x
EV / Sales 2018 6,13x
Capitalization 14 845 M
More Financials
Chart WATERS CORPORATION
Duration : Period :
Waters Corporation Technical Analysis Chart | WAT | US9418481035 | 4-Traders
Full-screen chart
Technical analysis trends WATERS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 179 $
Spread / Average Target -3,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Christopher James O'Connell President, Chief Executive Officer & Director
Douglas A. Berthiaume Chairman
David A. Terricciano Senior Vice President-Global Operations
Sherry L. Buck Chief Financial Officer & Senior Vice President
Edward W. Conard Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
WATERS CORPORATION38.01%14 845
THERMO FISHER SCIENTIF..23.63%68 244
DANAHER10.43%60 686
BOSTON SCIENTIFIC CORP..29.91%38 480
INTUITIVE SURGICAL49.64%34 960
ROYAL PHILIPS13.22%34 550
More Results